Compare Teradyne, Inc. (TER) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs 10X Genomics Inc — how do they compare? Teradyne, Inc. trades at $402.68 (market cap $62.34B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Teradyne, Inc. is far larger — about 6.2× 10X Genomics Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teradyne, Inc. for 37 Days and 10X Genomics Inc for 91 Days on average.
| TER | TXG | |
|---|---|---|
Market Cap | $62.34B | $10.07B |
Volume | 3,368,404 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $483.84 | $97.74 |
52-Week Low | $132.05 | $11.48 |
Typical Hold Time | 37 Days | 91 Days |
Enterprise Value | $62.08B | $9.59B |
Dividend Yield | 0.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $398.72, down 3.17% on the day, but maintains a bullish technical outlook with strong support at $388 and resistance at $410. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.47 exceeding the $2.09 estimate. Revenue for 2025 reached $3.19 billion, and net income margin stands at 25.77%. Recent developments include the launch of the Magnum E2 memory test system and Iris 100 for microLED devices, targeting AI and high-performance computing demand.
The outlook for TER is positive, driven by AI-driven test equipment demand and consistent earnings outperformance. Risks include reliance on semiconductor cycles and competitive pressure from peers like KLAC. Analysts are bullish with a consensus price target of $461.50, representing a 15.7% upside from the current price. Institutional buying and a lack of sell ratings underscore confidence in growth prospects.
TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.
The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
